Earnings
Ardelyx CEO Says 'We All Need To Be Patient' On Xphozah Outlook As Revenue Rises 7% To $29.2 Million
Xphozah sales grew 7% to $29.2 million while paid prescriptions rose 22%, and 2026 guidance of $110 million to $120 million stands.
ARDX
Ardelyx (ARDX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Ardelyx Faces A New Securities Class Action Reaching Back To January 2025
A September suit and an October derivative case target the drugmaker, which says it cannot estimate any loss.
SEC Filings
Ardelyx's IBSRELA Sales Climb 23% To $96.3 Million, Cutting Its Quarterly Loss To $0.7 Million
The drugmaker held its 2026 revenue and spending forecasts and finished enrolling its constipation trial ahead of schedule.